| Title |
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
|
|---|---|
| Published in |
Biologics in Therapy, January 2014
|
| DOI | 10.1007/s13554-014-0014-4 |
| Pubmed ID | |
| Authors |
Hans-Peter Schwarz, Dorota Birkholz-Walerzak, Mieczyslaw Szalecki, Mieczyslaw Walczak, Corina Galesanu, David Metreveli, Jasmin Khan-Boluki, Ellen Schuck |
| Abstract |
This prospective, open-label, non-comparative, multicentre, long-term phase IV study is examining the efficacy and safety of somatropin [recombinant human growth hormone (rhGH)] in short children born small for gestational age (SGA) and its impact on the incidence of diabetes. This report is the first interim analysis of patients who have completed 1 year of treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 15% |
| Student > Master | 4 | 15% |
| Student > Bachelor | 3 | 12% |
| Student > Ph. D. Student | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 31% |
| Nursing and Health Professions | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Agricultural and Biological Sciences | 1 | 4% |
| Psychology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2014.
All research outputs
#18,363,356
of 22,743,667 outputs
Outputs from Biologics in Therapy
#12
of 20 outputs
Outputs of similar age
#229,909
of 307,481 outputs
Outputs of similar age from Biologics in Therapy
#2
of 2 outputs
Altmetric has tracked 22,743,667 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.2. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,481 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.